Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

(2013) Masanori Noguchi et al.   BMC CANCER

Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer

(2013) A. Aruga et al.   CLINICAL CANCER RESEARCH

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity

(2013) Robert L. Elliott et al.   SURGICAL ONCOLOGY-OXFORD

Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma

(2012) E. H. J. G. Aarntzen et al.   CANCER RESEARCH

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

The immune score as a new possible approach for the classification of cancer

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

(2011) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

(2010) Masanori Noguchi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Selective addition of CXCR3+CCR4-CD4+ Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro

(2009) Sung Hee Yoon et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers

(2008) K. Imai et al.   CLINICAL CANCER RESEARCH

HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL

(2008) Michiko Harao et al.   INTERNATIONAL JOURNAL OF CANCER